Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Sharma East India Hospitals & Medical Research Ltd met on November 14, 2025 and approved the un-audited standalone financial results for Q2 and H1 FY26 (quarter and half year ended September 30, 2025). H1 FY26 revenue from operations grew about 20% YoY to Rs. 1,885.82 lakhs (vs Rs. 1,573.74 lakhs in H1 FY25), while profit after tax rose modestly to Rs. 63.58 lakhs (vs Rs. 58.97 lakhs). Q2 FY26 standalone revenue was Rs. 943.45 lakhs with a PAT of Rs. 31.78 lakhs and EPS of Rs. 0.97. Total assets stood at Rs. 3,147.04 lakhs as on September 30, 2025 (vs Rs. 2,767.46 lakhs on March 31, 2025). Operating cash flow for H1 was negative at Rs. (250.65) lakhs due to a sharp jump in current borrowings to Rs. 427.31 lakhs. Independent Director Shri. Rajeev Kumar resigned citing pre-occupation and personal commitments, vacating the Chairmanship of the Audit Committee and Nomination & Remuneration Committee, which were reconstituted with Srikant Vinayakrao Bulakh as the new Chairman of both committees.
For shareholders: Revenue growth in H1 FY26 is healthy at around 20% YoY, but margins remain thin and operating cash flow turned sharply negative, with a large increase in short-term borrowings that investors should monitor. The Independent Director's resignation and committee reshuffle are routine and unlikely to materially affect operations, though governance continuity should be tracked.